

## Resignation of Director

Milan (Italy), 30 July 2009 - MolMed S.p.A. (Milan:MLM), announces that Dr Francesco Marco Bongiovanni today communicated to the company his resignation from the position of non-independent and non-executive member of MolMed's Board of Directors, with immediate effect. Dr. Bongiovanni held no other position within the company.

### About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemias; NGR-hTNF, a novel vascular targeting agent (VTA), in Phase II in six different indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancers, and malignant pleural mesothelioma. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares (Milan:MLM) are listed on the Milan Stock Exchange, at the Standard segment (class I) of the MTA managed by Borsa Italiana.

For further information, please contact:

#### *Investor Relations:*

Holger Neecke  
*Director Business Development, IR*  
MolMed S.p.A.  
phone: +39 02 21277.205  
fax: +39 02 21277.325  
e-mail: investor.relations@molmed.com

#### *Administration, Finance & Control:*

Enrico Cappelli  
*Chief Financial Officer*  
MolMed S.p.A.  
phone: +39 02 21277.302  
fax: +39 02 21277.325  
e-mail: enrico.cappelli@molmed.com